PHARMACEUTICALS – Make In India #pharma #pharmaceutical #company


Posted On Apr 21 2017 by

#india pharma

#

SUMMARY

  • Third largest pharmaceuticals market by 2020 in terms of incremental growth.
  • 20% of global exports in generics, making it the largest provider of generic medicines globally.
  • USD 45 Billion in revenue by 2020, revenue of USD 55 billion by 2020 as base case, and can grow to USD 70 billion in a aggressive case scenario.
  • USD 26.1 Billion in generics by 2016.
  • USD 200 Billion to be spent on infrastructure by 2024.
  • India’s filing of Drug Master Files’s (DMF’s) with USFDA as of Dec 2013 is 3411, the highest filed by any country in the world.
  • Total exports of Drugs, Pharmaceuticals for 2013-14 at USD 15,095 million, recording a growth rate 2.5% over the corresponding period of previous years.

REASONS TO INVEST

  • India is expected to rank amongst the top three pharmaceutical markets in terms of incremental growth by 2020.
  • India will become the sixth largest market globally in terms of absolute size by zero.
  • India’s generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally.
  • India’s cost of production is significantly lower than that of the USA and almost half of that of Europe.
  • A skilled workforce as well as high managerial and technical competence.
  • Economic prosperity is likely to improve affordability for generic drugs in the market.
  • Approval time for new facilities has been drastically reduced.

STATISTICS

  • The country’s pharmaceuticals industry is expected to account for about 3.1-3.6% of the global pharma industry by value and currently accounts for 10% by volume, by 2016.
  • Industry revenues are expected to expand at a CAGR of 12.1% during 2012-20 and reach USD 45 Billion.
  • The healthcare sector in India is expected to grow to USD 250 Billion by 2020 from USD 65 Billion currently.
  • The generics market is expected to grow to USD 26.1 Billion by 2016 from USD 11.3 Billion in 2011.

GROWTH DRIVERS

  • Between 2011 and 2016, patent drugs worth USD 255 Billion are estimated to go off-patent leading to a huge surge in generic product and tremendous opportunities for companies.
  • By 2020, it will grow to USD 11 billion – a CAGR of 18%, with the potential to reach USD 13 billion – at an aggresive CAGR of 20%.
  • With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available.
  • Pharma companies have increased spending to tap rural markets and develop better infrastructure. The market share of hospitals is expected to increase from 13.1% in 2009 to 26% in 2020.
  • Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India.
  • The purported rise of lifestyle diseases in India is expected to boost industry sales figures.
  • Over USD 200 Billion is to be spent on medical infrastructure in the next decade.
  • Rising levels of education are set to increase the acceptability of pharmaceuticals.
  • India’s patient pool is expected to increase to over 20% in the next 10 years, mainly due to the rise in population.

FDI POLICY

  • 100% Foreign Direct Investment (FDI) is allowed under the automatic route for greenfield projects.
  • For brownfield project investments, up to 100% FDI is permitted under the government route.
  • The government may incorporate appropriate conditions for FDI in brownfield cases, at the time of granting approvals.
  • ‘Non-compete’ clauses are not allowed except in special circumstances, with the approval of the Foreign Investment Promotion Board.
  • The FDI is subject to applicable regulations and laws.

SECTOR POLICY

The National Pharmaceutical Pricing Policy, 2012 (NPPP-2012) has been notified on December 7, 2012.

The salient features of the NPPP-2O12 are as under:

  • The regulation of prices of drugs on the basis of the essentiality of drugs as specified under the National List of Essential Medicines (NLEM)- 2011.
  • The regulation of prices of drugs on the basis of regulating the prices of formulations only.
  • The regulation of prices of drugs on the basis of fixing the ceiling price of formulations through Market Based Pricing.
  • The provision of exemptions to drugs manufactured through indigenous R D from price control for five years.
  • A Drug Price Control Order 2013 has been notified in May 2013 to implement the provisions of NPPP-2012.

FINANCIAL SUPPORT

KEY PROVISIONS IN THE 2O15-16 UNION BUDGET:

  • SETU (Self Employment and Talent Utilization) to be established as a techno-financial, incubation and facilitation programme to support all aspects of a startup business. INR 10 Billion to be set aside as initial amount in NITI.
  • Atal Innovation Mission (AIM) to be established in NITI to provide an Innovation Promotion Platform involving academicians, and drawing upon national and international experiences to foster a culture of innovation, research and development. A sum of INR 1.5 Billion will be earmarked.
  • The threshold limit for applicability of transfer pricing regulations to specified domestic transactions increased from INR 0.05 billion to INR 0.2 Billion.
  • Service Tax exemption for common effluent treatment plant operators.
  • Rate of income tax on royalty and fees for technical services reduced from 25% to 10% to facilitate technology inflow.
  • Time limit for taking CENVAT credit on inputs and input services have been increased from six months to one year.

EXPORT INCENTIVES HAVE BEEN ENVISAGED IN THE FOLLOWING SCHEMES:

  • Focus product scheme.
  • Special focus product scheme.
  • Focus market scheme.
  • Export promotion capital goods scheme.

AREA-BASED INCENTIVES:

  • Incentives for units in SEZ/NIMZ as specified in respective acts.
  • Setting up of projects in special areas such as the North-east, Jammu Kashmir, Himachal Pradesh and Uttarakhand.

UNITS IN CLUSTERS:

  • A scheme for the development of common facilities like effluent treatment, testing centres etc.

STATE INCENTIVES:

  • Besides the above, each state in India offers additional incentives for industrial projects.
  • Incentives are in areas like subsidised land cost, relaxation in stamp duty on sale/lease of land, power tariff incentives, concessional rate of interest on loans, investment subsidies/tax incentives, backward areas subsidies, special incentive packages for mega projects etc.

R D BENEFITS:

Industry/private sponsored research programmes:

  • A weighted tax deduction is given under section 35 (2AA) of the Income Tax Act.
  • A weighted deduction of 200% is granted to assesses for any sum paid to a national laboratory, university or institute of technology, or specified persons with a specific direction provided that the said sum is used for scientific research within a programme approved by the prescribed authority.

Companies engaged in manufacture having an in-house R D centre:

  • Weighted tax deduction of 200% under section 35 (2AB) of the Income Tax Act for both capital and revenue expenditure incurred on scientific research and development. Expenditure on land and buildings are not eligible for deduction.
  • A national centre to help develop bulk drugs and facilitate their research is being set up in Hyderabad.
  • Duty free import of Pharmaceuticals reference standards.

INVESTMENT OPPORTUNITIES

  • India is expected to be the third largest global market for active pharmaceutical ingredients by 2016, with a 7.2% increase in market share.
  • Indian pharma companies registered 49% of overall DMF filed in the US in 2012.
  • The Contract Research and Manufacturing Services industry – estimated at USD 8 Billion in 2015, up from USD 3.8 Billion in 2012. The market has more than 1000 players.
  • The formulations industry – India is the largest exporter of formulations with 14% market share and ranks 12th in the world in terms of export value. Double-digit growth is expected over the next five years.

FOREIGN INVESTORS

  • Teva Pharmaceuticals (Israel)
  • Nipro Corporation (Japan)
  • Procter Gamble (USA)
  • Pfizer (USA)
  • Glaxo Smith Kline (UK)
  • Johnson Johnson (USA)
  • Otsuka Pharmaceutical (Japan)
  • AstraZeneca (Sweden-UK)

AGENCIES





Last Updated on: April 21st, 2017 at 8:56 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *